Vaccines: Classification and Pharmacovigilance

Purpose and Scope

Vaccines are biological medicinal products designed to induce an immune response that provides protection against an infectious disease or, in some circumstances, reduces the consequences of exposure to an infectious agent. Their pharmacovigilance differs in emphasis from that of many therapeutic medicines because vaccines are commonly administered to people who are healthy at the time of vaccination, may be given to very large populations, and are intended to produce a biological effect that persists beyond the time of administration. Safety surveillance must therefore interpret adverse events in the context of both the vaccine itself and the epidemiology of the disease and population in which vaccination occurs.

The diversity of vaccine technology makes classification important. A vaccine may contain a live attenuated organism, an inactivated organism, a purified antigen, a recombinant antigen, a conjugated antigen, a viral vector or nucleic acid such as messenger RNA. The platform determines how the antigen is presented to the immune system, but it does not by itself determine the complete safety profile. Formulation, adjuvants, excipients, manufacturing processes, route of administration, schedule, age group and target population may all contribute to the safety characteristics that need to be monitored.

This article establishes the type-level framework for vaccine pharmacovigilance within the QPPV.com biological-product series. It first explains what makes a vaccine a distinct biological medicinal product, then classifies the principal vaccine platforms and connects their characteristics to development, clinical use and safety. It subsequently examines vaccine-specific pharmacovigilance, including adverse-event interpretation, causality, population surveillance, product and batch traceability, signal detection, risk management, quality interfaces and inspection considerations. Individual vaccine products and detailed histories are reserved for later product-specific articles.

The article focuses primarily on vaccines for prophylaxis against infectious diseases, consistent with the scope of the EMA GVP product-specific guidance on vaccines. The general EU pharmacovigilance framework remains applicable; the vaccine-specific guidance adds considerations arising from the biological characteristics and use of vaccines rather than creating a separate pharmacovigilance system. [1]

What Makes a Vaccine a Distinct Pharmacovigilance Category?

The pharmacovigilance of vaccines begins with the nature of vaccination itself. A vaccine is administered with the intention of inducing an immune response, rather than primarily to treat an established disease. The expected biological response is therefore part of the therapeutic purpose. At the same time, the immune activation that produces protection can be associated with local or systemic reactions, and uncommon adverse events may occur independently of the intended immune response.

The distinction between an event occurring after vaccination and an adverse reaction caused by a vaccine is consequently fundamental. An adverse event is a temporal occurrence after administration and does not by itself establish causality. The EU GVP framework defines an adverse event as an untoward medical occurrence that does not necessarily have a causal relationship with treatment, while regulatory pharmacovigilance requirements concern adverse reactions. Vaccine safety assessment must therefore progress from temporal association to clinical, epidemiological, biological and other evidence supporting or refuting a causal relationship. [1,2]

The challenge is amplified by the populations in which vaccines are used. Vaccination programmes can cover a large proportion of a population over a relatively short period. In such circumstances, illnesses that would have occurred without vaccination will inevitably occur after vaccination by chance. The larger the vaccinated population, the more frequently rare background events can appear in temporal association with vaccination. This is one reason why vaccine pharmacovigilance requires methods capable of comparing observed events with appropriate background expectations rather than relying on temporal association alone. [1]

Vaccines also introduce a distinctive benefit–risk context. The benefit of vaccination is partly determined by the incidence, severity, transmissibility and epidemiology of the infectious disease being prevented. The balance can therefore change as disease incidence changes, as population immunity develops, or as vaccination programmes alter transmission. Vaccine safety assessment is consequently connected to population-level benefit–risk evaluation rather than being limited to the frequency of adverse events among vaccine recipients. [1]

Classification of Vaccines

Vaccine classification can be approached through several complementary dimensions. The most useful starting point for pharmacovigilance is the nature of the antigen and the biological platform used to generate the immune response. Additional dimensions include whether the organism is live or non-live, whether the antigen is produced directly or through recombinant technology, whether an adjuvant is present, and whether the vaccine uses a vector or nucleic acid to enable antigen production in the recipient.

The major platform categories can be summarised as follows:

These categories are not mutually exclusive in every scientific classification. A vaccine can be recombinant and protein-based, for example, while a conjugate vaccine may use a protein carrier produced through recombinant technology. The purpose of the classification is therefore not to force every vaccine into one box, but to identify the biological characteristics that are relevant to development and safety assessment.

The platform should also not be treated as a surrogate for the individual product. Two vaccines using the same broad platform can differ in antigen, formulation, adjuvant, manufacturing process, route of administration and target population. Shared platform characteristics may guide biological plausibility, but product-specific evidence determines the safety profile of the individual vaccine.

Live Attenuated Vaccines

Live attenuated vaccines contain organisms that remain biologically active but have been modified so that they have substantially reduced pathogenic potential under the intended conditions of use. Their ability to replicate can contribute to a strong and durable immune response, but it also creates safety questions that do not arise in the same form for non-live vaccines.

The relevant risks depend on the organism, attenuation strategy, route of administration and characteristics of the recipient. In particular, susceptibility to infection or altered immune control may differ between healthy individuals and people with specific immune deficiencies. A safety assessment therefore needs to consider the biological behaviour of the vaccine strain together with the characteristics of the population in which it is used.

For pharmacovigilance, this means that the product's mechanism of action and biological properties are directly relevant to case assessment. A suspected event potentially related to replication or dissemination cannot be evaluated solely from the timing of vaccination. The clinical phenotype, recipient susceptibility, microbiological evidence where available, known characteristics of the vaccine strain and relevant background disease must be considered.

Live vaccines also illustrate why vaccine pharmacovigilance cannot be separated from public-health context. The disease against which vaccination provides protection may itself have serious consequences, and the incidence of that disease affects the benefit side of the benefit–risk balance. The appropriate assessment therefore requires the vaccine risk to be interpreted against the risk of the infection being prevented.

Inactivated and Non-Living Whole-Organism Vaccines

Inactivated vaccines use organisms that have been rendered unable to replicate while retaining sufficient antigenic characteristics to induce an immune response. Because the organism cannot reproduce in the recipient, the safety questions associated with replication differ fundamentally from those of live attenuated vaccines.

The manufacturing process remains important because the quality and integrity of the antigen depend on how the organism is propagated, inactivated, purified and formulated. A change in process or an unexpected quality characteristic can therefore require scientific and regulatory assessment even when the basic vaccine platform has remained unchanged.

Non-living vaccines can also contain multiple components, including antigens, adjuvants, stabilisers, preservatives or other excipients. A reported adverse event may therefore require consideration of more than the antigen itself. The EMA vaccine pharmacovigilance guidance specifically recognises that vaccines are complex biological products and that individual components can have safety implications. [1]

The resulting pharmacovigilance approach is not to attribute an event automatically to one component, but to preserve enough product information and clinical detail to permit a component-specific hypothesis to be evaluated when the evidence warrants it.

Protein, Subunit, Recombinant and Conjugate Vaccines

Protein and subunit vaccines use selected antigenic components rather than the whole infectious organism. The components may be purified directly from a biological source or produced using recombinant technology. This approach allows the vaccine to be designed around defined antigens and can reduce exposure to biological material that is not needed for the intended immune response.

The pharmacovigilance implications depend on the antigen and formulation rather than on the word "subunit" alone. The protein may be combined with an adjuvant to enhance the immune response, and the formulation may contain stabilisers, preservatives or other excipients. The manufacturing process can also determine purity, aggregation, structural integrity and the presence of residual materials. These characteristics may influence reactogenicity or immune responses and therefore form part of the scientific context for safety assessment.

Conjugate vaccines add another layer of biological complexity by linking a polysaccharide antigen to a carrier protein. The conjugation changes the way the antigen is presented to the immune system and can improve the quality and persistence of the immune response, particularly in populations in which a plain polysaccharide response is less effective. Pharmacovigilance may consequently need to consider both the antigenic component and the carrier or formulation when evaluating a suspected reaction.

Recombinant vaccines illustrate why production technology and vaccine classification overlap. A recombinant antigen may be produced in bacteria, yeast, insect cells or another expression system and then purified and formulated as a vaccine. The vaccine remains a product intended to induce protective immunity, but its quality and safety characteristics also depend on the recombinant expression and purification process. This is one reason biological-product principles concerning manufacturing, characterisation, comparability and traceability remain relevant within vaccine pharmacovigilance. [1,3]

Viral-Vector and Nucleic-Acid-Based Vaccines

Some vaccines use a delivery platform rather than administering the antigen as a purified protein or whole organism. Viral-vector vaccines use a vector to deliver genetic information encoding an antigen. Nucleic-acid-based vaccines, including messenger RNA platforms, similarly provide genetic instructions that enable cells in the recipient to produce the antigen.

These technologies do not change the fundamental purpose of vaccination: the product is intended to generate an immune response against an infectious disease. They do, however, alter the biological pathway between administration and antigen exposure. The pharmacovigilance assessment therefore needs to consider both the antigen-specific immune response and the characteristics of the delivery platform.

For a viral-vector product, relevant characteristics can include whether the vector is replication competent, its tissue distribution, pre-existing or induced immunity to the vector, and the relationship between the vector and the encoded antigen. These features vary between products, so the existence of a vector platform does not by itself define a uniform safety profile.

For nucleic-acid-based vaccines, the relevant considerations include the nucleic-acid construct, the delivery system, the expression of the encoded antigen and the resulting innate and adaptive immune responses. The safety assessment remains product-specific and evidence-led. Novel technology should not be equated with an adverse effect, just as an established platform should not be assumed to be free of new safety information.

The EMA's vaccine pharmacovigilance framework explicitly recognises that novel vaccine technologies, delivery systems, adjuvants and routes of administration may create new safety concerns and may justify targeted monitoring or specific studies. [4] The operational implication is that the pharmacovigilance plan should be informed by the biological characteristics of the individual vaccine rather than by a generic platform label.

Adjuvants, Excipients and Residual Materials

A vaccine is often more than its antigen. Adjuvants may be used to enhance or shape the immune response, while stabilisers, preservatives and other excipients may be required for product performance and storage. Residual materials from the manufacturing process can also be relevant to the quality profile.

Adjuvants deserve particular attention because their intended function is to modify the immune response. Local and systemic reactions may therefore reflect the combined effects of antigen, adjuvant and the host immune response. The clinical interpretation of an event should consider the known characteristics of the complete formulation rather than assuming that the antigen is the only biologically active component.

The same principle applies to changes in formulation. Removal or substitution of an excipient, introduction of a new adjuvant, or modification of a manufacturing step may alter the product's characteristics and can require appropriate quality and regulatory assessment. A subsequent safety observation should not automatically be attributed to the change, but the pharmacovigilance system should preserve the information needed to investigate such a hypothesis when clinically and scientifically justified.

EMA's vaccine pharmacovigilance guidance specifically identifies adjuvants, stabilisers, preservatives and residual materials as potential contributors to vaccine safety considerations. [4] This does not mean that each component is an independent safety hazard. It means that the complete product composition is part of the evidence required to interpret a suspected adverse reaction.

Development of Vaccines and the Safety Baseline

Vaccine development establishes the scientific and clinical baseline against which post-authorisation safety information is interpreted. The development programme characterises the antigen and formulation, establishes manufacturing controls, evaluates non-clinical safety and immunogenicity, and generates clinical evidence in the populations for which the vaccine is intended.

The evidence needed to understand vaccine safety differs according to the platform and target population. A live attenuated vaccine may require particular attention to biological behaviour in susceptible hosts. A protein vaccine may require characterisation of the antigen, formulation and adjuvant. A vector-based vaccine may require evaluation of vector-specific biological properties. A vaccine intended for infants, older adults or immunocompromised individuals may also require population-specific evidence because the immune response and background risks differ.

The development programme does not establish that every adverse event occurring after authorisation is unrelated to the vaccine. Rather, it provides the prior knowledge needed to interpret new observations. Pharmacovigilance then extends that evidence base to larger populations, longer periods of use, different healthcare settings and less common outcomes.

This relationship is especially important for vaccines because pre-authorisation clinical trials are generally unable to observe every rare event that may occur after widespread use. When a vaccine is introduced into a large population, the resulting increase in exposure creates an opportunity to detect rare events, but it also creates the statistical challenge of distinguishing vaccine-related events from the expected incidence of unrelated disease.

Vaccination Programmes and Population-Level Exposure

The scale and organisation of vaccination programmes are central to vaccine pharmacovigilance. Vaccines may be offered routinely to defined age groups, targeted to people at increased risk, administered during outbreaks, or deployed rapidly during public-health emergencies. Each context changes the pattern of exposure and the background events against which safety observations are interpreted.

A routine childhood programme, for example, may involve repeated exposure of large birth cohorts and administration alongside other vaccines. An outbreak campaign may involve rapid vaccination of a population with a temporary increase in exposure over a short period. An emergency programme may require accelerated deployment, changing healthcare settings and unfamiliarity with the product among vaccinators. These circumstances can affect the volume, timing and quality of safety information available to pharmacovigilance.

The EMA GVP vaccine guidance identifies several population-level challenges: large numbers of reports may arise in a short period; coincidental illnesses will inevitably occur after vaccination; and conventional comparisons with an unvaccinated concurrent cohort may not always be available. [1] These features make epidemiological methods, background-rate information and active surveillance particularly important where a potential signal could plausibly be detected through population-level data.

Exposure estimation also has a specific meaning in vaccine pharmacovigilance. Depending on the question, relevant denominators may include doses administered, individuals vaccinated, person-time after vaccination or defined population cohorts. These measures are not interchangeable. A safety assessment should select the denominator that corresponds to the biological and epidemiological question being asked.

Adverse Events Following Immunisation and Adverse Reactions

The term adverse event following immunisation, or AEFI, is commonly used in vaccine safety to describe an untoward medical occurrence following immunisation without implying causality. EMA's GVP vaccine guidance notes that AEFIs can be categorised according to possible causes, including vaccine product-related events, quality-defect-related events, immunisation-error-related events and immunisation-anxiety-related events. [1]

This terminology is useful because it preserves the distinction between observation and causality. A patient may develop an illness after vaccination because of the vaccine, because of a quality problem, because of an error in the vaccination process, because of an anxiety-related response, or because the illness would have occurred independently of vaccination. The clinical observation is real in each case, but the causal explanation is different.

EU pharmacovigilance obligations are concerned with adverse reactions rather than every temporal AEFI. The assessment process therefore needs to move from the initial report to an evaluation of the evidence. Depending on the event, this can involve clinical chronology, alternative explanations, known vaccine effects, concomitant vaccination, epidemiological background rates, laboratory findings, biological plausibility, rechallenge information where applicable and evidence from other cases or studies.

The distinction also matters for communication. Describing an event as occurring "following vaccination" is not equivalent to stating that it was "caused by the vaccine." Maintaining this distinction in case processing, signal evaluation and safety communication protects the scientific integrity of the assessment while allowing potential concerns to be investigated promptly.

Causality Assessment in Vaccines

Causality assessment for vaccines is challenging because several features of vaccination reduce the usefulness of evidence that is often informative for therapeutic medicines. Many vaccines are administered once or at widely separated intervals, so dechallenge may have little meaning. Several vaccines may be administered during the same visit, making attribution to one product more difficult. Some adverse events also occur commonly in the general population, creating a substantial background rate.

The absence of a convincing temporal relationship does not necessarily exclude a causal association, and temporal association alone does not establish one. The strength of evidence depends on the specific event and vaccine. A biologically plausible mechanism, consistent clinical phenotype, reproducible epidemiological association, dose or schedule relationship, or other supporting evidence can strengthen a causal hypothesis. Conversely, a strong background incidence, an alternative clinical explanation or lack of association across appropriate studies can weaken it.

The assessment should therefore remain proportionate to the question. Individual case causality and population-level signal assessment are related but distinct activities. A case may be medically plausible without establishing a population-level association, while an epidemiological signal may warrant investigation even when individual cases are difficult to classify with certainty.

The EMA vaccine guidance emphasises that causality between vaccines and adverse events can be difficult to assess because of concomitant vaccination, high vaccination coverage and the inevitable occurrence of background diseases after vaccination. [1] These are structural features of vaccine use, not deficiencies in the pharmacovigilance system, and they explain why vaccine safety assessment often requires complementary evidence sources.

Signal Detection for Vaccines

Vaccine signal detection uses the same fundamental pharmacovigilance objective as signal detection for other medicinal products: to identify information that may indicate a new causal association, or a new aspect of a known association, that warrants further investigation. The methods and governance remain part of the general pharmacovigilance system, but vaccine-specific features influence which evidence is informative and how signals are interpreted.

Spontaneous reports can be particularly valuable when a vaccine is widely used because they provide an early source of information about rare or unexpected events. At the same time, spontaneous reporting cannot by itself establish incidence or causality. Reporting frequency is influenced by stimulated reporting, media attention, awareness of a potential association, changes in reporting systems and other factors that may be unrelated to a change in the underlying risk.

For vaccines, signal detection may therefore require triangulation across several evidence streams. These can include individual case reports, observed-to-expected analyses, epidemiological studies, clinical-trial data, literature, active surveillance, registries, electronic healthcare data and information from vaccine programmes. The appropriate combination depends on the vaccine, event, population, exposure pattern and scientific question.

The signal should also be defined at the correct level. A potential signal may concern an individual product, a vaccine platform, an antigen, an adjuvant, a manufacturing process or an administration error. These hypotheses are not equivalent. Product-specific evidence should not automatically be generalised to all vaccines using a related platform, while a plausible platform-level mechanism may justify examination of related products.

Observed Versus Expected Events

A central problem in vaccine safety surveillance is that vaccination occurs against a background of naturally occurring disease. When millions of people are vaccinated, some will develop serious illnesses shortly afterwards even if vaccination has no causal role. The number of coincidental events can therefore be substantial.

An observed event becomes more informative when its occurrence differs from what would be expected in a comparable population or time period, after taking account of the relevant sources of uncertainty. Observed-to-expected analyses can help identify unusual patterns, but they require reliable background rates and appropriate definitions of exposure, risk windows and population characteristics.

The choice of risk window is especially important. A window that is too broad can capture large numbers of unrelated background events, while a window that is too narrow may miss biologically plausible delayed effects. The appropriate window should be informed by the biological mechanism, existing evidence and the specific outcome under investigation.

A statistical excess does not itself prove causality. It identifies a pattern that may require further investigation. Conversely, the absence of an observed excess does not necessarily exclude a very rare association if the available exposure or outcome data lack sufficient power. Vaccine signal assessment therefore combines quantitative findings with clinical and biological interpretation.

Product and Batch Traceability in Vaccine Pharmacovigilance

Product traceability is particularly important for vaccines because large vaccination programmes can involve multiple products, presentations, manufacturing sites and batches. A safety observation may initially appear to concern vaccination in general, but later evidence may indicate that the relevant question concerns a specific vaccine product, formulation or batch.

The EMA GVP vaccine guidance emphasises the importance of brand-specific and, where appropriate, batch-specific pharmacovigilance. It notes that vaccine safety profiles can change over time as a result of manufacturing modifications, unintended quality deviations or other changes, and that this supports continuous surveillance and traceability. [1]

Traceability also supports the investigation of product-quality concerns. If an unexpected cluster is reported, the organisation may need to determine whether the cases involve the same product, the same batch, the same manufacturing site or a common administration setting. Without reliable product identification, these hypotheses can become difficult to test.

Traceability should not be interpreted as evidence that a cluster is batch-related. It is an enabling control that preserves the information needed to determine whether a batch hypothesis is supported. The investigation must then integrate pharmacovigilance, quality, manufacturing and epidemiological evidence.

Vaccination Errors and Administration-Related Events

Vaccination safety is affected not only by the intrinsic characteristics of the vaccine but also by the way it is stored, prepared and administered. Errors can involve the wrong vaccine, wrong dose, incorrect route, incorrect schedule, inappropriate storage or handling, or administration to a person for whom the vaccine is not recommended.

An administration error is not equivalent to a product defect. The pharmacovigilance assessment should preserve the distinction while ensuring that a medically significant event following an error is appropriately evaluated and recorded under the applicable regulatory and organisational processes.

The distinction is important because the corrective action may differ. A product-related safety issue may require assessment of the product's benefit–risk balance, product information or risk minimisation. An administration error may instead require changes to training, labelling, packaging, storage procedures or vaccination practice. Some events may involve more than one contributing factor, so the investigation should not force a complex event into a single causal category prematurely.

Quality Defects and Vaccine Pharmacovigilance

Vaccine quality defects can have direct safety implications and may require coordination between quality and pharmacovigilance functions. Examples of quality information that may become relevant include contamination, incorrect potency, unexpected impurities, stability problems, container or closure problems, or deviations from an approved manufacturing process.

The existence of a quality defect does not automatically establish that an adverse event was caused by the defect. Conversely, an emerging pattern of adverse events may be an early indication that a quality investigation is warranted. The two evidence streams should therefore be connected through defined escalation and information-sharing processes.

A robust investigation should preserve the chronology of the product, batch, manufacturing information, clinical observations and regulatory decisions. Where a potential safety concern is linked to a batch or quality characteristic, the evidence should support reconstruction of what was distributed, who may have been exposed and whether the observed clinical pattern is compatible with the proposed mechanism.

This is an example of why vaccine pharmacovigilance is broader than individual case processing. The safety system must be capable of connecting clinical reports with product quality, distribution, manufacturing and population-level evidence when the safety question requires it.

Immunogenicity and Vaccine Safety

Immunogenicity is inherent to the purpose of vaccination, but the intended immune response should not be equated with an adverse reaction. Vaccine development seeks to generate protective immunity while maintaining an acceptable safety profile. The pharmacovigilance question is therefore whether the immune response, or another component of the product, contributes to an unwanted clinical outcome.

The nature of the immune response depends on the vaccine platform, antigen, adjuvant, route, schedule and recipient. Local injection-site reactions, fever and other short-lived systemic reactions may represent expected pharmacodynamic or immune effects. Rare immune-mediated diseases or hypersensitivity reactions require a different level of investigation because their frequency, clinical severity and biological plausibility differ.

For some vaccines, pre-existing immunity or previous vaccination can modify the response to subsequent doses. The interpretation of an event may therefore depend on vaccination history rather than on the most recent dose alone. This reinforces the importance of accurate exposure history and product identification.

The vaccine-specific approach is consequently not to label immune activation as inherently safe or inherently harmful. It is to distinguish expected immune effects from clinically important adverse reactions and to investigate unexpected or disproportionate patterns using the evidence appropriate to the vaccine and outcome.

Risk Management for Vaccines

Risk management for vaccines follows the general EU framework but must account for the characteristics of vaccination and the populations in which vaccines are used. The safety specification should reflect important identified and potential risks, missing information and the scientific uncertainties relevant to the individual vaccine.

Additional pharmacovigilance activities may be appropriate when routine surveillance is unlikely to answer an important safety question. Depending on the product and uncertainty, these can include post-authorisation safety studies, active surveillance, registries, enhanced monitoring or targeted epidemiological studies. The selection of an activity should be driven by the safety question rather than by the fact that the product is a vaccine.

Risk minimisation can also operate at several levels. Product information may provide contraindications, warnings and precautions; healthcare-professional information may address preparation or administration; educational measures may reduce preventable vaccination errors; and programme-level measures may support appropriate use. These interventions should be connected to the identified risk and evaluated where effectiveness assessment is required.

Vaccines also require careful consideration of communication because safety information can affect confidence in vaccination programmes. Communication should distinguish confirmed risks, suspected signals under investigation, background events and events that have not been shown to be causally related. Clear communication is therefore part of effective risk management, while the underlying scientific assessment must remain independent of communication objectives.

Benefit–Risk Evaluation of Vaccines

The benefit–risk balance of a vaccine differs from that of a medicine used to treat an established disease because the principal benefit is prevention. The relevant benefit depends on the incidence and severity of the infectious disease, the vaccine's effectiveness, the duration of protection, population coverage and, where relevant, indirect effects such as reduced transmission.

The risk side includes expected reactions, identified adverse reactions, potential risks and uncertainties. Because vaccines are frequently administered to healthy individuals, the tolerance for serious vaccine-related harm may be low even when the absolute risk is very small. At the same time, an extremely rare adverse reaction may need to be considered against a substantial risk from the disease that the vaccine prevents.

Benefit–risk evaluation is therefore dynamic. Changes in disease epidemiology, circulating strains, population immunity, vaccine effectiveness, alternative vaccines or treatment options can alter the balance. A safety signal should be evaluated within this broader context rather than interpreted in isolation from the disease burden and vaccination programme.

Roles and Cross-Functional Interfaces

Effective vaccine pharmacovigilance commonly requires coordinated information from functions that hold different parts of the evidence. Pharmacovigilance may need clinical information from medical teams, product and process information from quality and manufacturing, regulatory information from regulatory affairs, exposure and programme information from public-health or distribution functions, and epidemiological expertise for population-level assessment.

The precise organisational structure is not prescribed as a single model for all organisations. The essential control is that responsibilities and interfaces are sufficiently defined for relevant safety information to reach the appropriate assessment function without avoidable delay.

These interfaces should be governed through defined responsibilities and records rather than relying on informal communication. The objective is to make the evidence chain reconstructable when a safety question crosses functional boundaries.

Evidence and Records

The evidence needed for vaccine pharmacovigilance depends on the safety question, but the system should preserve enough information to reconstruct the exposure, the clinical observation, the assessment and the decision. At the individual-case level, relevant information may include the exact vaccine product, dose, date and route of administration, batch or lot where available, vaccination history, concomitant vaccines or medicines, clinical chronology, diagnosis, investigations and outcome.

At signal level, the evidence set may additionally include cumulative case data, observed-to-expected analyses, epidemiological studies, clinical-trial evidence, literature, active surveillance results, product-quality information, manufacturing information and regulatory assessments. The purpose is not to collect every possible data source for every signal. It is to ensure that the evidence selected is capable of answering the question being assessed.

Records should make the reasoning traceable. A reviewer should be able to determine what information was available, which hypotheses were considered, how alternative explanations were assessed, what uncertainties remained and why the conclusion or action was proportionate to the evidence. This is particularly important when vaccine safety questions attract substantial public or regulatory attention, because the assessment may later need to be reconstructed from the underlying evidence rather than from a summary conclusion alone.

Practical Implementation

A vaccine pharmacovigilance system can be assessed through the sequence in which information becomes available. The first control is reliable identification of the vaccine administered. The second is capture of sufficient clinical information to characterise the event. The third is access to the scientific, epidemiological and product-quality evidence needed to evaluate causality and detect patterns. The final controls concern governance, documentation, escalation and regulatory action.

A practical implementation model is:

1. Identify the product and exposure. Capture the vaccine product and relevant presentation, dose, date, route, batch information where available, and vaccination history.
2. Characterise the event. Establish the clinical phenotype, chronology, investigations, outcome and relevant alternative explanations.
3. Place the event in context. Consider concomitant vaccination, medicines, underlying disease, age, population, background incidence and the relevant infectious-disease epidemiology.
4. Evaluate the evidence. Integrate individual cases with cumulative, epidemiological, clinical, literature, quality and mechanistic evidence as appropriate.
5. Determine the level of the concern. Establish whether the evidence supports an individual product, batch, component, platform or broader vaccine-class hypothesis.
6. Manage the risk. Where warranted, update risk characterisation, initiate additional investigation, consider risk minimisation or regulatory action, and communicate appropriately.
7. Document and follow through. Preserve the evidence, reasoning, decisions, responsibilities and subsequent effectiveness or follow-up activities.

This sequence is a practical operating model rather than an additional legal requirement. The applicable EU GVP modules, product-specific guidance, legislation and product documentation determine the mandatory regulatory framework.

Common Failure Modes

Vaccine pharmacovigilance can be weakened by several recurring types of error. These are illustrative failure modes rather than claims about particular inspection findings.

Treating every post-vaccination event as vaccine-related

A temporal association is mistaken for causality, particularly when the event is common in the background population. This can inflate perceived risk and divert assessment resources from more informative patterns.

Treating vaccine-relatedness as impossible to establish without a rechallenge

Because many vaccines are administered once or have long-lasting immunological effects, dechallenge and rechallenge are often not informative. Absence of rechallenge evidence should not prevent a scientifically appropriate assessment using other evidence sources.

Aggregating related vaccines too early

Cases are combined across vaccines because they target the same disease or use a similar platform. This can obscure product-specific differences and make it difficult to determine whether a signal is associated with one product, a component, or a broader platform.

Losing batch information

Batch details are treated as optional administrative information rather than as part of the traceability system. When a quality or batch hypothesis later emerges, the missing information limits the ability to investigate exposure patterns.

Treating a quality deviation as proof of a clinical safety problem

A manufacturing or quality finding is automatically interpreted as a pharmacovigilance signal without evidence that the deviation affected the product or clinical outcome. Quality and pharmacovigilance evidence must be integrated, not conflated.

Ignoring the vaccination programme context

A signal is assessed without considering coverage, background incidence, concomitant vaccination, seasonal disease patterns or changes in disease epidemiology. This can produce misleading observed-to-expected comparisons or inappropriate causal conclusions.

Allowing communication pressure to replace scientific assessment

Public concern or intense media attention can increase reporting and accelerate the need for communication. It should not, however, determine the scientific conclusion. The evidence and uncertainty should remain explicit even when rapid action is necessary.

Inspection Perspective

An inspection of vaccine pharmacovigilance would be expected to focus on whether the organisation has translated the vaccine-specific characteristics into effective controls within its general pharmacovigilance system. Illustrative inspection questions include:

• Can the organisation identify the exact vaccine product involved in a safety report?
• Can relevant batch or lot information be retrieved when a product- or batch-specific question arises?
• Are vaccine-specific safety considerations reflected in the relevant safety specification and pharmacovigilance activities?
• Can the organisation distinguish an event occurring after vaccination from an adverse reaction attributed to the vaccine?
• Are concomitant vaccines and relevant vaccination history available for assessment?
• Can the organisation obtain appropriate background-rate or epidemiological information when a population-level signal is investigated?
• Are quality defects, manufacturing changes and pharmacovigilance concerns connected through defined interfaces?
• Can the organisation reconstruct the evidence and reasoning behind a significant vaccine-safety decision?
• Are regulatory actions, risk-minimisation measures and follow-up activities traceable to the assessment that justified them?

These questions are illustrative and do not represent a list of prescribed inspection findings. The underlying inspection principle is effectiveness: the organisation should be able to demonstrate that its vaccine pharmacovigilance controls work in practice, not merely that procedures describing them exist.

Actionable Checklist

Before considering vaccine pharmacovigilance controls effective for a product, an organisation should be able to answer the following questions:

The checklist is an operational aid, not a substitute for the applicable legal requirements or product-specific pharmacovigilance plan.

Relationship With the Wider Pharmacovigilance Framework

Vaccine pharmacovigilance is governed by the same fundamental principles that apply to other medicinal products. Individual case safety reporting, signal management, risk management, periodic safety evaluation, safety communication, quality management and regulatory oversight remain part of the general system. The vaccine-specific layer exists because vaccination introduces distinctive biological and epidemiological circumstances that change the evidence required for effective application of those processes.

The EMA GVP vaccine guidance expressly states that the overall objectives and processes of pharmacovigilance are not different for vaccines and other medicinal products; its purpose is to address vaccine-specific aspects and unique challenges that should be considered when designing and implementing pharmacovigilance activities. [1] This principle should remain visible throughout the QPPV.com series. Vaccine pharmacovigilance is not a parallel discipline. It is product-specific application of the general pharmacovigilance framework.

The distinction also helps prevent unnecessary duplication across the QPPV.com knowledge base. General articles on signal management, risk management, aggregate reporting, case processing and inspections provide the underlying processes. This vaccine article explains how those processes are affected by vaccination, vaccine technology and population-level exposure. Later individual-vaccine articles can then concentrate on product-specific evidence and history.

Key Takeaways

Vaccines are biological medicinal products whose pharmacovigilance is shaped by both their biological technology and the way they are used. They are commonly administered to healthy people, often on a large population scale, and their intended effect is to generate protective immunity. These characteristics make temporal associations common and causality challenging to establish.

Vaccine platforms include live attenuated, inactivated, protein or subunit, polysaccharide, conjugate, recombinant, vector-based and nucleic-acid-based approaches. These categories overlap, and the platform should be treated as a source of scientific context rather than as a substitute for individual product identity.

The safety profile of a vaccine reflects the complete medicinal product: antigen, vector or nucleic acid where applicable, adjuvants, excipients, manufacturing process, formulation, route and schedule, together with the characteristics of the vaccinated population. Product and batch traceability are therefore important controls, particularly when a safety or quality hypothesis may be product- or batch-specific. [1]

Vaccine safety assessment must distinguish adverse events following vaccination from adverse reactions causally associated with a vaccine. Effective signal assessment often requires triangulation of spontaneous reports with epidemiological, clinical, literature, quality and mechanistic evidence. Population-level background rates and disease epidemiology are particularly important because coincidental events are inevitable when vaccination is widespread.

The appropriate pharmacovigilance system is therefore neither a generic adverse-event collection process nor a separate vaccine-only system. It is the general EU pharmacovigilance framework applied with product-specific scientific understanding, traceability, epidemiological context, cross-functional governance and evidence proportionate to the safety question.

References

1. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Product- or Population-Specific Considerations I — Vaccines for prophylaxis against infectious diseases. EMA/488220/2012. Legal effective date 13 December 2013. This is the principal EU GVP guidance used for vaccine-specific pharmacovigilance considerations.
2. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Annex I — Definitions. Rev. 5, EMA/876333/2011, effective 6 August 2024. Relevant definitions include adverse event and adverse reaction.
3. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Product- or Population-Specific Considerations II — Biological medicinal products. EMA/168402/2014, effective 16 August 2016. Relevant to biological-product principles that also apply to vaccines, including product characteristics and traceability.
4. European Medicines Agency. Guideline on the conduct of pharmacovigilance for vaccines for pre- and post-exposure prophylaxis against infectious diseases. EMEA/CHMP/PhVWP/503449/2007. Relevant scientific and operational background on novel vaccines, adjuvants, excipients, manufacturing-related considerations and long-term safety monitoring.
5. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. Relevant provisions concerning medicinal-product pharmacovigilance and biological medicinal products.
6. European Parliament and Council. Regulation (EC) No 726/2004, as amended. EU framework for the authorisation, supervision and pharmacovigilance of medicinal products within its scope.
7. European Medicines Agency. Good pharmacovigilance practices (GVP). Current GVP framework and product- or population-specific considerations. EMA's current GVP overview confirms the vaccine-specific chapter as part of the final GVP framework and notes that the guidance is subject to revision as legislation and ICH guidance evolve.
8. World Health Organization. Global manual on surveillance of adverse events following immunization. WHO guidance on vaccine-safety surveillance, including AEFI concepts and surveillance approaches. Used as complementary international scientific guidance rather than as an EU legal source.

Regulatory Note

The legal framework for vaccine pharmacovigilance derives from applicable EU pharmaceutical and pharmacovigilance legislation. EMA GVP provides regulatory guidance on how pharmacovigilance requirements are applied, including vaccine-specific considerations. The operational models, distinctions and checklists in this article are intended to explain and implement those principles; they should not be interpreted as additional legal requirements unless the underlying requirement is expressly identified as such.

The principal EMA vaccine-specific GVP guidance currently dates from 2013, while the wider GVP framework continues to evolve. EMA's current GVP overview records ongoing review of the modules and the effect of legislative amendments and new ICH guidance on future revisions. Current legislation, GVP guidance, product information, risk-management documentation and applicable national requirements should therefore be verified before the article is used to support a regulatory or operational decision.

The term AEFI is used in this article in its vaccine-safety sense to describe an event following immunisation without implying causality. EU pharmacovigilance obligations concern adverse reactions as defined in the applicable framework. This distinction should be maintained in case processing, signal assessment and safety communication.